Lilly shuffles key executive positions; Mikael Dolsten takes another...
→ Eli Lilly is making some adjustments to its team: Patrik Jonsson and Ilya Yuffa will trade places as Jonsson becomes president of Lilly International, while Yuffa succeeds Jonsson with an ...
View ArticleIntroducing the new Endpoints profile experience
We’ve got some exciting upgrades coming to the Endpoints platform this year. Today, we’re launching the first step — a new profile experience — which will serve as a single place to access and manage...
View ArticleLonza says its US-based sites are in high demand as pharma tariffs near
Lonza said on Friday it does not expect any “material financial impact” from current and potential pharma-specific tariffs, as the Swiss CDMO fields inquiries for its US-based facilities ...
View ArticleRevolution’s KRAS drugs appear competitive in several lung cancer settings
Revolution Medicines revealed new data that suggest its closely watched KRAS-targeting cancer programs could be highly competitive with similar therapies already on the market. The biotech’s shares...
View ArticleAstraZeneca reports Phase 3 win for Imfinzi; Roche to build new manufacturing...
Plus, news about Sanofi, IGM Biosciences, Eli Lilly, Purdue University, Minghui, Qilu, Sirius Therapeutics, Keros Therapeutics, Palatin and Leo Pharma: 💉AstraZeneca touts Imfinzi Phase 3 win in...
View ArticleChronic care startup Omada Health files to go public
Virtual diabetes and chronic care startup Omada Health filed to go public on Friday, making it the second digital health company to do so this year as the sector shows signs of picking up after ...
View ArticleMakary names Vinay Prasad CBER chief; Q1 earnings report; More on “Most...
Welcome back to Endpoints Weekly — thanks for starting your Saturday with us. It was a busy week in the biopharma world. FDA Commissioner Marty Makary picked a new CBER chief to replace Peter Marks,...
View ArticleTrump confirms 'most favored nation' drug price plans
President Donald Trump said he'll take executive action to have the US pay no more than other countries for drugs, a move that would expand price controls and is almost certain to generate strident...
View ArticleLilly says further head-to-head trial data back Zepbound over Novo’s Wegovy
Eli Lilly said Sunday that new data on Zepbound show the GIP/GLP-1 dual agonist is a better weight loss drug than Novo Nordisk’s Wegovy. Almost 65% of obese or overweight people treated with Zepbound...
View ArticleTrump signs ‘most favored nation’ order to try to lower US drug prices
The White House plans to force down prices of drugs sold in the US by threatening to tie costs to rates paid by other countries, a directive that could have huge impacts but is almost ...
View ArticleFDA clears in vivo blood stem cell editing trial; Abeona's $155M PRV sale
Plus, news about CytomX, Valneva, Lenz and Lotus Pharmaceutical: 🧪 After China, US greenlights first trial of in vivo blood stem cell editing: Ensoma
View ArticleExclusive: Patrick Hsu’s startup Stylus Medicine launches, looks beyond...
Stylus Medicine, an ambitious startup founded by Patrick Hsu, has raised $85 million to develop a suite of technologies that it believes will help solve some of the biggest and most competitive ...
View ArticleRoche could rethink $50B US expansion plan if new policies 'harm' operations
Roche said its $50 billion promise to expand its manufacturing footprint in the US has the potential to be “reassessed” — the same day the Swiss pharma added further details on how it would spend part ...
View ArticleRepublican tax cut bill includes PBM, drug price negotiation changes
The latest version of a massive and wide-ranging tax cut bill includes several pro-pharma reforms related to pharmacy benefit managers and the way the drug price negotiation program deals with orphan...
View ArticleTrump's drug price plan is light on details, may have little impact
The White House's plan to realign US drug prices with similar high-income countries has ignited a wave of questions about how or even if drug companies will come to the table and work with the ...
View ArticlePharma investors brush off Trump’s ‘most favored nation’ plan as stocks rise
President Donald Trump on Monday made a sweeping promise to bring down drug prices and stop pharma companies from taking advantage of the US. Wall Street seems unfazed. As details of Trump’s
View ArticleDutch biotech Azafaros gets $146M for Phase 3 trials in three metabolic...
The last time Dutch biotech Azafaros disclosed a financing round — a €25 million Series A — the world was a few weeks away from Covid-19 lockdowns. Five years and three months later, the ...
View ArticleBayer Q1 earnings: 2,000 jobs cut as it homes in on year-end rehaul target
Bayer has been ramping up layoffs in recent months as it edges closer to its end-of-year target to complete its management reorganization that was first announced in 2023. The German conglomerate ...
View Article